Total Payments
$16,348
2024 Payments
$1,500
Companies
4
Transactions
38
Medicare Patients
222
Medicare Billing
$53,912
Payment Breakdown by Category
Research$8,169 (50.0%)
Consulting$6,050 (37.0%)
Travel$1,204 (7.4%)
Food & Beverage$925.06 (5.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,169 | 16 | 50.0% |
| Consulting Fee | $6,050 | 3 | 37.0% |
| Travel and Lodging | $1,204 | 4 | 7.4% |
| Food and Beverage | $925.06 | 15 | 5.7% |
Payments by Type
General
$8,179
22 transactions
Research
$8,169
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $15,792 | 35 | $0 (2024) |
| iSchemaView, Inc. | $350.00 | 1 | $0 (2023) |
| Grifols Shared Services North America, Inc. | $115.02 | 1 | $0 (2017) |
| ACADIA Pharmaceuticals Inc | $90.13 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,500 | 1 | Biogen, Inc. ($1,500) |
| 2023 | $350.00 | 1 | iSchemaView, Inc. ($350.00) |
| 2022 | $3,534 | 14 | Biogen, Inc. ($3,534) |
| 2020 | $2,231 | 2 | Biogen, Inc. ($2,231) |
| 2019 | $3,045 | 3 | Biogen, Inc. ($3,045) |
| 2018 | $5,482 | 15 | Biogen, Inc. ($5,482) |
| 2017 | $205.15 | 2 | Grifols Shared Services North America, Inc. ($115.02) |
All Payment Transactions
38 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/10/2024 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction | ||||||
| 05/31/2023 | iSchemaView, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 10/19/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $34.31 | General |
| 10/05/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $80.86 | General |
| 10/05/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $80.40 | General |
| 10/05/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $61.26 | General |
| 10/05/2022 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $44.96 | General |
| 10/05/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $31.85 | General |
| 10/05/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $31.85 | General |
| 10/04/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $225.94 | General |
| 10/04/2022 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $128.57 | General |
| 10/04/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $80.40 | General |
| 10/04/2022 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $10.49 | General |
| 10/04/2022 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $5.71 | General |
| 09/30/2022 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $817.20 | General |
| 07/06/2022 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,900.00 | Research |
| Study: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction | ||||||
| 12/07/2020 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,900.00 | General |
| 02/18/2020 | Biogen, Inc. | — | — | Cash or cash equivalent | $331.25 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 06/11/2019 | Biogen, Inc. | — | — | Cash or cash equivalent | $2,850.00 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 02/07/2019 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $83.04 | General |
| 02/05/2019 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $112.24 | General |
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $61.47 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $58.99 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $40.10 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $29.84 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | Biogen, Inc. | $4,769 | 14 |
| Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction | Biogen, Inc. | $3,400 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 59 | 98 | $55,299 | $14,422 |
| 2021 | 3 | 88 | 130 | $73,519 | $19,634 |
| 2020 | 2 | 75 | 118 | $71,664 | $19,856 |
Total Patients
222
Total Services
346
Medicare Billing
$53,912
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 40 | 69 | $47,991 | $12,044 | 25.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 29 | $7,308 | $2,379 | 32.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 62 | 92 | $63,058 | $16,363 | 25.9% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2021 | 12 | 19 | $5,697 | $1,705 | 29.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 19 | $4,764 | $1,566 | 32.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 62 | 99 | $66,045 | $18,107 | 27.4% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2020 | 13 | 19 | $5,619 | $1,749 | 31.1% |
About Holly Hinson, M.D., MCR
Holly Hinson, M.D., MCR is a Neurocritical Care healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2007. The National Provider Identifier (NPI) number assigned to this provider is 1780711135.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Holly Hinson, M.D., MCR has received a total of $16,348 in payments from pharmaceutical and medical device companies, with $1,500 received in 2024. These payments were reported across 38 transactions from 4 companies. The most common payment nature is "" ($8,169).
As a Medicare-enrolled provider, Hinson has provided services to 222 Medicare beneficiaries, totaling 346 services with total Medicare billing of $53,912. Data is available for 3 years (2020–2022), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurocritical Care
- Other Specialties Neurology, Student in an Organized Health Care Education/Training Program
- Location San Francisco, CA
- Active Since 02/27/2007
- Last Updated 03/13/2023
- Taxonomy Code 2084A2900X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780711135
Products in Payments
- Thrombate III (Biological) $115.02
- NUPLAZID (Drug) $90.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.